Medications for Diffuse Large Bcell Lymphoma

11 results

  • adcetris - brentuximab vedotin injection, powder, lyophilized, for solution

    (Brentuximab Vedotin)
    Seagen Inc.
    ADCETRIS treats classical Hodgkin lymphoma (untreated, consolidation, or relapsed), systemic and cutaneous anaplastic large cell lymphoma, CD30-expressing mycosis fungoides, peripheral T-cell lymphomas, and relapsed/refractory large B-cell lymphoma in adults; and high-risk cHL in pediatric patients 2 years and older.
    Medication Details
    Savings Programs
    1
    Drug Interactions

  • breyanzi

    (Lisocabtagene Maraleucel)
    Juno Therapeutics, Inc.
    Breyanzi is a CD19-directed CAR-T cell immunotherapy for adults with relapsed or refractory large B-cell lymphoma, CLL/SLL, follicular lymphoma, mantle cell lymphoma, or marginal zone lymphoma after 2 or more prior lines of therapy. Not indicated for primary CNS lymphoma.
    Medication Details

  • columvi - glofitamab concentrate

    (Glofitamab)
    Genentech, Inc.
    Columvi treats adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL, NOS) or large B-cell lymphoma arising from follicular lymphoma, after two or more prior lines of systemic therapy.
    Medication Details
    Drug Interactions

  • epkinly - epcoritamab - bysp injection, solution

    (Epcoritamab-Bysp)
    Genmab Us, Inc.
    Epkinly treats adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma after 2+ prior therapies. Also indicated for relapsed or refractory follicular lymphoma (FL), with lenalidomide and rituximab or as monotherapy after 2+ prior therapies.
    Medication Details
    Drug Interactions

  • kymriah

    (Tisagenlecleucel)
    Novartis Pharmaceuticals Corporation
    Kymriah is a CD19-directed CAR-T cell therapy for patients up to 25 with refractory or relapsed B-cell precursor ALL; adults with relapsed/refractory large B-cell lymphoma after 2+ prior therapies; and adults with relapsed/refractory follicular lymphoma after 2+ prior therapies (accelerated approval).
    Medication Details
    Drug Interactions

  • monjuvi

    (Tafasitamab-Cxix)
    Incyte Corporation
    Monjuvi (tafasitamab), combined with lenalidomide, treats adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL from low-grade lymphoma, who are ineligible for autologous stem cell transplant. Approved under accelerated approval based on overall response rate.
    Medication Details
    Drug Interactions

  • polivy - polatuzumab vedotin injection, powder, lyophilized, for solution

    (Polatuzumab Vedotin)
    Genentech, Inc.
    Polivy treats adults with diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma. Used with R-CHP for previously untreated DLBCL/HGBL (IPI ≥2), and with bendamustine plus rituximab for relapsed or refractory DLBCL after at least two prior therapies.
    Medication Details
    Drug Interactions

  • rituxan hycela - rituximab and hyaluronidase injection, solution

    (Rituximab And Hyaluronidase)
    Genentech, Inc.
    Rituxan Hycela treats adult patients with follicular lymphoma (relapsed/refractory, previously untreated, or non-progressing after CVP), previously untreated diffuse large B-cell lymphoma with chemotherapy, and previously untreated or treated chronic lymphocytic leukemia with fludarabine and cyclophosphamide. Requires prior IV rituximab dose.
    Medication Details
    Drug Interactions

  • xpovio

    (Selinexor)
    Karyopharm Therapeutics Inc.
    Xpovio (selinexor) treats adult multiple myeloma patients after prior therapies, in combination with bortezomib/dexamethasone or dexamethasone alone. Also indicated for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after at least 2 prior systemic therapy lines.
    Medication Details
    Drug Interactions

  • yescarta

    (Axicabtagene Ciloleucel)
    Kite Pharma, Inc.
    Yescarta is a CAR-T cell therapy for adults with large B-cell lymphoma refractory to or relapsing after first-line chemoimmunotherapy, or after two or more prior therapies. Also indicated for relapsed or refractory follicular lymphoma after two or more lines of systemic therapy (accelerated approval).
    Medication Details
    Drug Interactions